Table 1.

Summary of the effects reported in preclinical studies in different tendon conditions

Condition	Blood-derived products	Bone marrow-derived products	Adipose tissue-derived products
Complete/partial ruptures	Improved histologic appearance and ECM deposition (16/16) Reduction of inflammatory markers (5/5) Improvement of biomechanical properties (8/12)	Improved histologic appearance and ECM deposition (2/3)	Improved histologic appearance and ECM deposition (5/6) Improved biomechanical properties (10/11) Improved MRI appearance (1/3) Improved functional outcomes (2/2)
Tendinopathies	Improved histologic appearance (7/8) Improvement of biomechanical properties (1/2) Improved US and MRI appearance (3/3)	Improved histologic appearance (1/1) Improvement of biomechanical properties (1/1) Reduction of MMPs expression (2/2) Improved functional outcomes (1/1)	Improved histologic appearance and ECM deposition (4/4) Improved biomechanical properties (2/2)
Rotator Cuff Tears	Improved histologic appearance (2/4) Improved biomechanical properties (mid-term follow-up) (7/7) Improvements identified by imaging and functional assessment (1/1)	Improved histologic appearance (1/1) Improvement of biomechanical properties (1/1)	Improved histologic appearance (3/4) Improved biomechanical properties (4/5) Improved MRI appearance (1/1) Improved functional outcome (1/1)
Lesion of the enthesis	Improved histologic appearance and ECM deposition (4/5) Improved biomechanical properties (3/3)	Improved histologic appearance and ECM deposition (1/1) Improved biomechanical properties (4/4) Improved radiographic appearance (1/1) Improved functional outcomes (1/1)	Improved histologic appearance and ECM deposition (4/5) Improvement observed by microCT and Rx (2/2)

ECM extracellular matrix, GFs growth factors, mCT microcomputed tomography, Rx X-ray

Number in parentheses reports the fraction of studies confirming the results among total number of studies assessing the specific outcome (studies with positive results/number of studies)